The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation announced they will combine in a first-of-its-kind transaction in cancer philanthropy to launch the Samuel Waxman Institute for Aging & Cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

2025 Lasker awards announced

Top row (left to right): Dirk Görlich, Steven L. McKnight, Michael J. Welsh.Bottom row (left to right): Jesús (Tito) González, Paul A. Negulescu, Lucy ShapiroThe 2025 Albert Lasker Basic Medical Research Award honors went to two scientists for discoveries that exposed the structures and functions of low-complexity domains  within protein sequences. 
Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Clinical Roundup

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account